Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical... see more

CSE:BIOV - Post Discussion

BioVaxys Technology Corp. > 1 million shares traded today with U.S OTC 881k CDN
View:
Post by frankman on Dec 09, 2024 3:32pm

1 million shares traded today with U.S OTC 881k CDN

Sym-X Bid - Ask Last Chg %Ch Vol $Vol #Tr
ATS 226.1 0.05 · 0.06 72.0 0.055 -0.005 -8.3 881.8 42 152
CSE - C 226.1 0.05 · 0.06 72.0 0.055 -0.005 -8.3 399.9 20 54
NEO ATS - U   0.055 -0.005 -8.3 85.0 4 15
Omega - O   0.055 -0.005 -8.3 219.0 11 25
Chi-X - X   0.055 -0.005 -8.3 1.0   1
CX2 - H   0.055 -0.005 -8.3 160.5 7 38
CXD - D   0.06     1.2   5
TriAct - M   0.06     5.2   13
CS2 - S   0.055 -0.005 -8.3 10.0 1 1
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities